Cohen Cheryl 4

What Happened

• Cheryl Cohen, a director of ImmunityBio, was granted an award of 65,600 shares on 2026-06-09. The filing reports the shares were acquired at $0.00 (a derivative equity award), meaning no cash purchase was made at grant. The award is subject to vesting conditions described in the filing.

Key Details

• Transaction date: 2026-06-09; filing date (Accession): 2026-06-10.
• Transaction type/code: A — Grant / Award (derivative), 65,600 shares, acquisition price $0.00.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Vesting note (footnote F1): 100% of the shares will vest on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders, provided Cohen remains a Service Provider under the 2025 Equity Incentive Plan.
• Remarks include Exhibit 24 — Power of Attorney.
• Filing appears timely (reported the day after the transaction).

Context

• This was an equity award (likely restricted stock or RSUs) that vests based on continued service; it is a derivative grant rather than an open-market purchase or sale. Such awards do not require immediate cash and do not by themselves indicate a buy/sell market signal until vested shares are sold or purchased.